Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 672 of the 672 references it cites were found in a registry or an index; 168 of the 876 sources its claims cite were checked for support.

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Open access
Xie, Xin, Yu, Tingting, Li, Xiang, Zhang, Nan, Foster, Leonard J., Peng, Cheng, Huang, Wei, He, Gu · 2023 · Signal Transduction and Targeted Therapy

Abstract

Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human diseases and has attracted substantial efforts in the field of medicine. Therefore, in this review, we focus on the recent development of drug discovery targeting “undruggable” proteins and their application in clinic. To make this review well organized, we discuss the design strategies targeting the undruggable proteins, including covalent regulation, allosteric inhibition, protein–protein/DNA interaction inhibition, targeted proteins regulation, nucleic acid-based approach, immunotherapy and others.

Overview

CoChat Summary

TL;DR

This review surveys drug-discovery strategies for "undruggable" proteins — targets with flat, pocketless interfaces such as KRAS, phosphatases, transcription factors, and PPI-driven proteins — covering covalent regulation, allosteric modulation, PPI/protein–DNA inhibition, targeted protein degradation and stabilization, nucleic acid approaches, and immunotherapy. It catalogs marketed drugs, clinical candidates, and preclinical leads across these modalities, framing the field's shift from "undruggable" to "difficult to drug" or "yet to be drugged."

Key findings

  • Covalent inhibition produced the field's landmark success: sotorasib (AMG-510) received FDA accelerated approval in May 2021 for KRASG12C-mutated NSCLC, with an overall remission rate of 37%, disease control rate of 81%, median PFS 6.8 months, and median duration of remission 10.0 months; adagrasib (MRTX-849) followed with ORR 58%, median duration of treatment 9.5 months, and median duration of remission 12.6 months.
  • Clinical-stage covalent KRASG12C inhibitors report ORRs including JAB-21822 56.3% (18/32, DCR 90.6%), divarasib 46% confirmed ORR (26/57 evaluable NSCLC patients), D-1553 37.8% (28/74, DCR 91.9%), JDQ-443 57% (4/7) at the phase II recommended dose, and IBI-351 50.9% (28/55) overall with 61.9% (13/21) at the recommended dose.
  • Allosteric modulators target undruggable proteins lacking orthosteric pockets: MRTX-1133 binds inactive KRASG12D with IC50 < 2 nM and ~700-fold selectivity over KRASWT; SHP2 allosteric inhibitors (TNO-155, JAB-3068, RMC-4630, JAB-3312, RLY-1971, BBP-398, ERAS-601, SH3809, ET-0038, ICP-189) have entered clinical trials though none are approved.
  • Targeted protein degradation extends to previously undruggable targets: PROTACs degrade KRASG12C (LC-2, DC50 0.25 μM in NCI-H23), Bcl-2/Bcl-xL (DT2216 in phase I), SHP2 (SHP2-D26, DC50 2.6 nM in MV4;11), MDM2/p53 (MD-224, IC50 1.5 nM), STAT3 (KT-333 in phase I), and c-Myc pathway proteins; molecular glues degrade IKZF1/3 and Cyclin K.

Methods

  • Narrative review, not primary research: the authors organize drug-discovery strategies for undruggable proteins into covalent regulation, allosteric modulation, PPI and protein–DNA interaction inhibition, targeted protein regulation (degradation/stabilization), nucleic acid-based approaches, immunotherapy, and other approaches (upstream/downstream effectors, synthetic lethality, PTMs, conjugates).
  • Evidence base is the published literature and trial registries: six summary tables (Tables 1–6) compile compound name/structure, target, cancer cell line activity, indications, status/clinical trial identifier, and references, with clinical trial data collected from ClinicalTrials.gov (last accessed March 2023).
  • Undruggable target classes defined as small GTPases (RAS family), phosphatases (PTPs, PSTPs), transcription factors (p53, Myc, ER, AR, XBP1, NRF2, NF-κB, BACH), epigenetic targets, and other proteins including PPI- and intrinsically disordered proteins.

Limitations

  • The paper states that a lack of accurate structural information on undruggable proteins remains a significant obstacle, and that cryo-EM low resolutions still need to be addressed; it also notes that genetic therapies such as therapeutic RNAs and synthetic lethal screening are limited by off-target effects and side effects.
  • The paper states that for marketed drugs, upcoming resistance is a major challenge that must be foreseen and protective plans developed; it also notes that most existing modulators are inhibitors, so activators (e.g., for p53) and PPI stabilizers remain underexplored.
  • Evident from the text: many cited clinical trials are listed as completed, terminated, withdrawn, or ongoing with results "pending publication" or not posted, so several efficacy claims rest on conference abstracts, company reports, or unpublished data rather than peer-reviewed results; the review also relies heavily on preclinical cell-line IC50/DC50 values that may not translate clinically.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01589-z

Cites

672 of 672 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Covalent modulators targeting undruggable proteins. Covalent inhibitors bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity. a Binding modes of selected covalent modulators: covalent KRAS inhibitors bind to the cystine of KRASG12C mutants to reduces the affinity between GTP and KRAS, thereby locking the KRASG12C mutant in an inactivated state; covalent EGFR inhibitors bind to Cys797 at ATP binding site of EGFR, showing high affinity for T790M mutants and solving resistance; covalent p53 stabilizers bind to p53-Y220C mutant to restore thermal stability to the wild-type level, or prevent the interaction between MDM2 and p53. b Map of marketed, clinical and preclinical covalent inhibitors in signaling pathways
Fig. 1 Covalent modulators targeting undruggable proteins. Covalent inhibitors bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity. a Binding modes of selected covalent modulators: covalent KRAS inhibitors bind to the cystine of KRASG12C mutants to reduces the affinity between GTP and KRAS, thereby locking the KRASG12C mutant in an inactivated state; covalent EGFR inhibitors bind to Cys797 at ATP binding site of EGFR, showing high affinity for T790M mutants and solving resistance; covalent p53 stabilizers bind to p53-Y220C mutant to restore thermal stability to the wild-type level, or prevent the interaction between MDM2 and p53. b Map of marketed, clinical and preclinical covalent inhibitors in signaling pathwaysCC BY · PubMed Central
Fig. 2 Allosteric inhibitors targeting undruggable proteins. Allosteric modulators change the protein/substrate affinity by stabilizing target proteins in an inactive or active state “at a distance”. a Binding mode of selected allosteric modulators: RAS allosteric inhibitors interact with mutant amino acids in switch II region to induce conformational changes, thereby locking KRAS in an inactive conformation; SHP2 allosteric inhibitors directly stabilize the autoinhibited conformation of SHP2, thereby preventing interactions between the catalytic PTP domain and SHP2 substrates; GPCR allosteric inhibitors can be classified into PAMs, allosteric antagonists and NAMs based on their mode of action. b Map of marketed, clinical and preclinical allosteric inhibitors in signaling pathways
Fig. 2 Allosteric inhibitors targeting undruggable proteins. Allosteric modulators change the protein/substrate affinity by stabilizing target proteins in an inactive or active state “at a distance”. a Binding mode of selected allosteric modulators: RAS allosteric inhibitors interact with mutant amino acids in switch II region to induce conformational changes, thereby locking KRAS in an inactive conformation; SHP2 allosteric inhibitors directly stabilize the autoinhibited conformation of SHP2, thereby preventing interactions between the catalytic PTP domain and SHP2 substrates; GPCR allosteric inhibitors can be classified into PAMs, allosteric antagonists and NAMs based on their mode of action. b Map of marketed, clinical and preclinical allosteric inhibitors in signaling pathwaysCC BY · PubMed Central
Fig. 3 PPI inhibitors and protein–DNA interaction inhibitors targeting undruggable proteins. a Binding modes and mechanisms of PPI modulators: according to binding modes, PPI modulators can be categorized as orthosteric or allosteric modulators; according to mechanisms, PPI modulators can be categorized as PPI inhibitors and PPI activators. b Map of marketed, clinical and preclinical PPI modulators and protein-DNA interaction inhibitors in signaling pathways. PPI inhibitors targeting RAS include RAS-RAF inhibitors, RAS-SOS inhibitors and RAS-PDEδ inhibitors. Bcl-2 PPI inhibitors restore the function of pro-apoptotic proteins such as Bax and Bad through blocking their interactions with anti-apoptotic protein Bcl-2. P53-MDM2 inhibitors restore the tumor-suppressing function of p53. PPI inhibitors targeting Myc include Myc-Max inhibitors, Myc-WDR5 inhibitors and Myc-TRRAP inhibitors. Protein-DNA interaction inhibitors have been used in targeting undruggable TFs
Fig. 3 PPI inhibitors and protein–DNA interaction inhibitors targeting undruggable proteins. a Binding modes and mechanisms of PPI modulators: according to binding modes, PPI modulators can be categorized as orthosteric or allosteric modulators; according to mechanisms, PPI modulators can be categorized as PPI inhibitors and PPI activators. b Map of marketed, clinical and preclinical PPI modulators and protein-DNA interaction inhibitors in signaling pathways. PPI inhibitors targeting RAS include RAS-RAF inhibitors, RAS-SOS inhibitors and RAS-PDEδ inhibitors. Bcl-2 PPI inhibitors restore the function of pro-apoptotic proteins such as Bax and Bad through blocking their interactions with anti-apoptotic protein Bcl-2. P53-MDM2 inhibitors restore the tumor-suppressing function of p53. PPI inhibitors targeting Myc include Myc-Max inhibitors, Myc-WDR5 inhibitors and Myc-TRRAP inhibitors. Protein-DNA interaction inhibitors have been used in targeting undruggable TFsCC BY · PubMed Central
Fig. 4 Targeted proteins regulation strategies targeting undruggable proteins. a Mechanisms of selected targeted proteins regulation strategies: PROTAC, LYTAC, ATTEC, and AUTOTAC utilize an “event-driven” degradation process instead of an “occupancy-driven” binding mechanism, allowing them to target and degrade undruggable proteins of interest (POIs) through proteasomal or lysosomal degradation pathways. b Map of marketed, clinical and preclinical targeted proteins regulation molecules in signaling pathways. PROTAC, in particular, has demonstrated the ability to degrade previously deemed undruggable POIs such as SHP2, KRAS, Bcl-2, and p53, as well as regulate TFs including STAT3, FoxM1, and c-Myc. Additionally, molecular glues have been utilized for the degradation of undruggable targets, such as IKZF and Cyclin K
Fig. 4 Targeted proteins regulation strategies targeting undruggable proteins. a Mechanisms of selected targeted proteins regulation strategies: PROTAC, LYTAC, ATTEC, and AUTOTAC utilize an “event-driven” degradation process instead of an “occupancy-driven” binding mechanism, allowing them to target and degrade undruggable proteins of interest (POIs) through proteasomal or lysosomal degradation pathways. b Map of marketed, clinical and preclinical targeted proteins regulation molecules in signaling pathways. PROTAC, in particular, has demonstrated the ability to degrade previously deemed undruggable POIs such as SHP2, KRAS, Bcl-2, and p53, as well as regulate TFs including STAT3, FoxM1, and c-Myc. Additionally, molecular glues have been utilized for the degradation of undruggable targets, such as IKZF and Cyclin KCC BY · PubMed Central
Fig. 5 Selected chemical structures of targeted protein regulator targeting undruggable proteins. PROTAC technology targets the degradation of undruggable targets, such as KRAS, Bcl-2, Cyclin D1, STAT3, SPH2, FoxM1, C-MYC, and p53, which share two common E3 ubiquitin ligase ligands. Other innovative technologies, such as molecular glues for targeted degradation of IkZF, ATTEC for targeting mHTTh or Tau, and DUBTAC for targeting TF, have also shown promise in targeting undruggable targets
Fig. 5 Selected chemical structures of targeted protein regulator targeting undruggable proteins. PROTAC technology targets the degradation of undruggable targets, such as KRAS, Bcl-2, Cyclin D1, STAT3, SPH2, FoxM1, C-MYC, and p53, which share two common E3 ubiquitin ligase ligands. Other innovative technologies, such as molecular glues for targeted degradation of IkZF, ATTEC for targeting mHTTh or Tau, and DUBTAC for targeting TF, have also shown promise in targeting undruggable targetsCC BY · PubMed Central
Fig. 6 Nucleic acid-based approaches and cases targeting undruggable proteins. a Antisense oligonucleotides (ASOs) inhibit translation of RNAs thereby targeting undruggable proteins. b RNA interference (RNAi) triggers the degradation of particular RNAs thereby down-regulating undruggable proteins. c CRISPR/Cas9 edits mutant oncogenic allele thereby targeting undruggable proteins. d G-quadruplex (G4) stabilizer regulates c-Myc transcription thereby targeting the undruggable Myc
Fig. 6 Nucleic acid-based approaches and cases targeting undruggable proteins. a Antisense oligonucleotides (ASOs) inhibit translation of RNAs thereby targeting undruggable proteins. b RNA interference (RNAi) triggers the degradation of particular RNAs thereby down-regulating undruggable proteins. c CRISPR/Cas9 edits mutant oncogenic allele thereby targeting undruggable proteins. d G-quadruplex (G4) stabilizer regulates c-Myc transcription thereby targeting the undruggable MycCC BY · PubMed Central
Fig. 7 Immunotherapy approaches and cases targeting undruggable proteins. a mRNA vaccines targeting p53 and KRAS. b Synthetic peptides vaccines targeting p53 and KRAS. c Immune system engineering targeting p53 and KRAS includes adoptive cell therapy and T cell receptor (TCR)-like antibodies. d Undruggable protein-related gene mutations lead to a cancer-supportive tumor immune microenvironment (TIME)
Fig. 7 Immunotherapy approaches and cases targeting undruggable proteins. a mRNA vaccines targeting p53 and KRAS. b Synthetic peptides vaccines targeting p53 and KRAS. c Immune system engineering targeting p53 and KRAS includes adoptive cell therapy and T cell receptor (TCR)-like antibodies. d Undruggable protein-related gene mutations lead to a cancer-supportive tumor immune microenvironment (TIME)CC BY · PubMed Central

Verification

Claims the paper makes

98 Valid · 25 Not valid · 463 Not checked · 121 Own results and interpretations

286 more claims · 45 with their cited sources checked

Create a free account to see all 707 claims and to verify the 708 references still open.

See all claims — free account
  • It may state two separate claims as one. 382
  • Probably not a substantial claim. 57
  • The quote only partly states this claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 8 · the rest aren’t loaded

3 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

1 retracted

Show all 670 references

Research works printed but not linked: 1

  1. Meng, J. After the AACR Conference, what new drugs are worth watching? https://baijiahao.baidu.com/s?id=1730615953532632799&wfr=spider&for=pc (2022).

Cited by

See all 435

Metadata

Authors
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G.
Affiliations
  • University of British Columbia (CA)
  • Chengdu University of Traditional Chinese Medicine (CN)
  • Sichuan University (CN)
Corresponding author
  • Peng, Cheng
  • Huang, Wei
  • He, Gu
Venue
Signal Transduction and Targeted Therapy
Published
2023-09-06
Volume
8
Issue
1
Pages
335-335
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4386446579
Cited by
396
References
670
Citations by year
2026: 127 · 2025: 173 · 2024: 92 · 2023: 4
FWCI
10.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (22177084, 82104373, 82073998)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
undruggable proteins, drug discovery, covalent drug design, allosteric inhibition, protein-protein interaction inhibition, nucleic acid therapeutics, immunotherapy, clinical translation
MeSH terms
Humans, Immunotherapy, Nucleic Acids, Drug Design, Drug Delivery Systems, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. https://app.cochat.ai/papers/10.1038/s41392-023-01589-z
The paper
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023). Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01589-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.